• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cytokinetics (NQ: CYTK )

    57.08 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 57.08
    Bid (Size) 52.60 (1)
    Ask (Size) 68.82 (1)
    Prev. Close 57.08
    Today's Range 57.08 - 57.08
    52wk Range 25.98 - 110.25
    Shares Outstanding 95,640,600
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    CYTK Stock Earnings: Cytokinetics Misses EPS, Misses Revenue for Q2 2024
    CYTK stock results show that Cytokinetics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Cytokinetics' Wild Ride: Can Investors Forgive The Royalty Pharma Deal?
    CEO Robert Blum says there are key components to the funding arrangement with Royalty Pharma that investors are missing. 
    Via Investor's Business Daily

    Performance

    YTD
    -32.14%
    -32.14%
    1 Month
    +6.83%
    +6.83%
    3 Month
    +14.46%
    +14.46%
    6 Month
    -15.66%
    -15.66%
    1 Year
    +62.34%
    +62.34%

    More News

    Read More
    7 Biotech Stocks to Boost Your Portfolio to Peak Health
    Via InvestorPlace
    Peering Into Cytokinetics's Recent Short Interest
    Via Benzinga
    June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
    Via InvestorPlace
    Dow Dips Over 550 Points; BJ's Wholesale Club Earnings Beat Views
    Via Benzinga
    Topics Earnings Stocks
    Exposures Financial US Equities
    (CYTK) - Analyzing Cytokinetics's Short Interest
    Via Benzinga
    $100 Invested In Cytokinetics 5 Years Ago Would Be Worth This Much Today
    Via Benzinga
    Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe
    Via Benzinga
    8 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Stocks Mixed Amid Flood Of Economic Data
    Via Talk Markets
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Gold Falls Sharply; US Composite PMI Surges In May
    Via Benzinga
    Why Cytokinetics (CYTK) Shares Are Falling
    Via Benzinga
    Why NVIDIA Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    NVIDIA To Rally Over 39%? Here Are 10 Top Analyst Forecasts For Thursday
    Via Benzinga
    VF Corp Posts Weak Q4 Results, Joins NetEase, Cytokinetics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
    From Royalty Pharma plc; Cytokinetics
    Via GlobeNewswire
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Cytokinetics Reveals More From The Study That Boosted Shares 83% In A Day
    Via Investor's Business Daily
    CYTK Stock Earnings: Cytokinetics Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
    Via InvestorPlace
    3 Biotech Stocks to Buy on the Dip: April 2024
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.